依托考昔治疗膝骨关节炎的短期疗效及安全性观察

目的 观察依托考昔治疗膝骨关节炎(OA) 的疗效和安全性.方法 选择25 例膝OA 患者,口服依托考昔,60mg,3 次/d.分别在0 周和第3 周末进行疗效和安全性评估,疗效指标包括WOMAC 骨关节炎指数评分(包括疼痛、僵硬、日常活动难度三个亚指标)、患者膝痛评分、患者对病情评分和医生对病情评分.治疗后指标改善≥ 30% 为有效.结果 经过3 周的依托考昔治疗,指标均有明显改善(P<0.01),除僵硬外其他指标改善超过30% 的比例均≥ 68%,其中膝痛指标的改善有效率达80%.5 例(20%) 发生可能与药物相关的不良反应,主要为胃肠道症状及肿胀,不需调整药物剂量或停药症状可好转.无严重不良事件发生.结论 依托考昔对膝OA 症状有较好的改善作用,短期使用不良反应轻,依从性好.

Short-term therapeutic effect of etoricoxib on knee osteoarthritis and its safety

Objective To observe the therapeutic effect of etoricoxib on knee osteoarthritis(OA) and its safety.Methods Twenty-five patients with knee OA were treated with oral etoricoxib at the dose of 60mg/d.Its therapeutic effect and safety were assessed at weeks 0 and 3,such as Western Ontario McMaster Universities Osteoarthritis(WOMAC) index score(pain,stiffness,and daily activity difficulty),score of knee pain and disease given by patients,and score of disease given by physicians.The treatment was judged effectively when the improved index was≥30%.Results All the indexes were significantly improved 3 weeks after treatment with etoricoxib(P<0.01).The therapeutic effect was≥68% except for stiffness and 80% for knee pain.Adverse reaction,mainly manifested as gastrointestinal symptoms and edema,occurred in 5 patients(20%),which improved without reducing the dose or withdrawal of etoricoxib.No severe adverse events occurred.Conclusion Etoricoxib can improve the symptoms of knee OA with mild adverse reaction and good compliance.